Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Undergraduate School

Miami University

1975, Oxford, OH

Graduate School

University of Cincinnati

1982, Cincinnati, OH

Medical School

University of Cincinnati College of Medicine

1982, Cincinnati, OH

Internship

Pediatrics

Boston Children's Hospital

1984, Boston, MA

Residency

Child Neurology

Washington University/Children’s Hospital

1987, St. Louis, MO

Fellowship

Neurobiology

Washington University

1990, St. Louis, MO

Certifications

  • American Board of Psychiatry and Neurology (Child and Adolescent Neurology)

Professional History

Dr. Pomeroy is the Bronson Crothers Professor of Neurology at Harvard Medical School. He graduated with MD and PhD degrees from the University of Cincinnati, trained in Pediatrics at Boston Children's Hospital and in Child Neurology at Washington University in St. Louis. He joined the faculty of Boston Children's Hospital and Harvard Medical School in 1991. In 2005, he was appointed as Neurologist-in-Chief of Boston Children's Hospital and Chair of the Department of Neurology at Harvard Medical School.

Media

Innovation Summit

Closing the Gap from Discovery to Treatment

Research

(L-R) Drs. Scott Pomeroy, David DeMaso, and R. Michael Scott

Publications

  1. An Approach to Successful Development of Clinician-Scientists in Neurology: The NINDS R25 Experience. Ann Neurol. 2024 Oct; 96(4):625-632. View Abstract

  2. WNT signalling control by KDM5C during development affects cognition. Nature. 2024 Mar; 627(8004):594-603. View Abstract

  3. Developmental basis of SHH medulloblastoma heterogeneity. Nat Commun. 2024 01 08; 15(1):270. View Abstract

  4. Clinical variants paired with phenotype: A rich resource for brain gene curation. Genet Med. 2024 03; 26(3):101035. View Abstract

  5. Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nat Genet. 2023 Dec; 55(12):2189-2199. View Abstract

  6. Recognizing and Responding to the Needs of Future Child and Adult Neurology Care Through the Evolution of Residency Training. Ann Neurol. 2023 12; 94(6):1005-1007. View Abstract

  7. Global neurology: It's time to take notice. Ann Clin Transl Neurol. 2023 05; 10(5):842-845. View Abstract

  8. Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers. J Neurodev Disord. 2022 03 23; 14(1):24. View Abstract

  9. SEQing to find hidden medulloblastoma cells. Cancer Cell. 2021 11 08; 39(11):1452-1454. View Abstract

  10. Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol. 2021 08 20; 39(24):2685-2697. View Abstract

  11. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Lett. 2021 04 28; 504:137-145. View Abstract

  12. Loss of Consciousness in the Young Child. Pediatr Cardiol. 2021 Feb; 42(2):234-254. View Abstract

  13. Crisis Standard of Care: Management of Infantile Spasms during COVID-19. Ann Neurol. 2020 08; 88(2):215-217. View Abstract

  14. Epigenetics and survivorship in pediatric brain tumor patients. J Neurooncol. 2020 Oct; 150(1):77-83. View Abstract

  15. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2020 02; 139(2):223-241. View Abstract

  16. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. 2019 09 16; 36(3):302-318.e7. View Abstract

  17. Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. Ann Neurol. 2019 09; 86(3):332-343. View Abstract

  18. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79. View Abstract

  19. Medulloblastoma. Nat Rev Dis Primers. 2019 02 14; 5(1):11. View Abstract

  20. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018 09 10; 34(3):396-410.e8. View Abstract

  21. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018 Nov; 140(2):269-279. View Abstract

  22. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798. View Abstract

  23. Brain cancer genomics and epigenomics. Handb Clin Neurol. 2018; 148:785-797. View Abstract

  24. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 07 19; 547(7663):311-317. View Abstract

  25. MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. Cancer Lett. 2017 08 10; 401:20-32. View Abstract

  26. The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 2017; 6:490. View Abstract

  27. Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics. 2017 04; 14(2):265-273. View Abstract

  28. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov. 2017 03; 7(3):288-301. View Abstract

  29. Tracking the Fate of Cells in Health and Disease. N Engl J Med. 2016 Dec 22; 375(25):2494-2496. View Abstract

  30. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 2017 Feb; 49(2):289-295. View Abstract

  31. The Evolution of Child Neurology Training. Pediatr Neurol. 2017 01; 66:3-4. View Abstract

  32. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol. 2016 Jun; 12(6):1297-302. View Abstract

  33. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 06; 131(6):821-31. View Abstract

  34. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016 08 01; 22(15):3903-14. View Abstract

  35. A clinic devoted to peer victimization in special needs children. Ann Neurol. 2016 Feb; 79(2):167-8. View Abstract

  36. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View Abstract

  37. Defining the molecular landscape of ependymomas. Cancer Cell. 2015 May 11; 27(5):613-5. View Abstract

  38. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174. View Abstract

  39. The G protein a subunit Gas is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014 Sep; 20(9):1035-42. View Abstract

  40. Could a5-GABA-A receptor activation be used as a target for managing medulloblastomas? CNS Oncol. 2014 Jul; 3(4):245-7. View Abstract

  41. Modelling high myc medulloblastoma and other brain tumors using human neural stem cells. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii4. View Abstract

  42. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303. View Abstract

  43. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17; 25(3):393-405. View Abstract

  44. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014 Feb 27; 506(7489):445-50. View Abstract

  45. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20; 32(9):886-96. View Abstract

  46. A developmental program drives aggressive embryonal brain tumors. Nat Genet. 2014 Jan; 46(1):2-3. View Abstract

  47. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb; 127(2):189-201. View Abstract

  48. a5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol. 2014 Apr; 127(4):593-603. View Abstract

  49. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. View Abstract

  50. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29. View Abstract

  51. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7. View Abstract

  52. Message from the incoming editor. Ann Neurol. 2013 Sep; 74(3):A9-A10. View Abstract

  53. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35. View Abstract

  54. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32. View Abstract

  55. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View Abstract

  56. Clinical practice guidelines and practice parameters for the child neurologist. J Child Neurol. 2013 Jul; 28(7):917-25. View Abstract

  57. Activation of ß-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene. 2014 Feb 13; 33(7):933-8. View Abstract

  58. A novel syndrome caused by the E410K amino acid substitution in the neuronal ß-tubulin isotype 3. Brain. 2013 Feb; 136(Pt 2):522-35. View Abstract

  59. Sport-related concussion: time to take notice. Curr Opin Pediatr. 2012 Dec; 24(6):687-8. View Abstract

  60. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec; 12(12):818-34. View Abstract

  61. Medulloblastoma biology in the post-genomic era. Future Oncol. 2012 Dec; 8(12):1597-604. View Abstract

  62. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10. View Abstract

  63. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56. View Abstract

  64. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5. View Abstract

  65. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug; 13(8):838-48. View Abstract

  66. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle. 2012 May 15; 11(10):1956-65. View Abstract

  67. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View Abstract

  68. Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol. 2012 Jun 10; 30(17):2154-6. View Abstract

  69. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):539-52. View Abstract

  70. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr; 123(4):473-84. View Abstract

  71. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr; 123(4):465-72. View Abstract

  72. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):529-38. View Abstract

  73. Recent advances in autism spectrum disorders. Curr Opin Pediatr. 2011 Dec; 23(6):607-8. View Abstract

  74. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr; 123(4):615-26. View Abstract

  75. Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell. 2011 Aug 16; 20(2):133-4. View Abstract

  76. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View Abstract

  77. Training the next generation of child neurologists - a neuroscience based approach. Ann Neurol. 2011 Jun; 69(6):A9-A10. View Abstract

  78. Molecular fingerprints of medulloblastoma and their application to clinical practice. Future Oncol. 2011 Mar; 7(3):327-9. View Abstract

  79. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23. View Abstract

  80. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med. 2011 Mar; 17(3):347-55. View Abstract

  81. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011 Feb 01; 2:180. View Abstract

  82. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011 Feb; 13(2):165-75. View Abstract

  83. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View Abstract

  84. Growing spectrum and relevance of pediatric neuro-immunology. Curr Opin Pediatr. 2010 Dec; 22(6):717. View Abstract

  85. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View Abstract

  86. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010 Dec; 16(12):1429-33. View Abstract

  87. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19; 18(4):316-28. View Abstract

  88. Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol. 2010 Dec; 12(12):1244-56. View Abstract

  89. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. View Abstract

  90. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell. 2010 Jan 08; 140(1):74-87. View Abstract

  91. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 08; 16(6):533-46. View Abstract

  92. Pathologic intracellular signaling in childhood pilocytic astrocytomas. Neurology. 2009 Nov 10; 73(19):1522-3. View Abstract

  93. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology. 2009 Jul 28; 73(4):323-5. View Abstract

  94. Pediatric sleep medicine in 2008: state-of-the-art. Curr Opin Pediatr. 2008 Dec; 20(6):639-40. View Abstract

  95. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol. 2008 Oct; 28(20):6223-33. View Abstract

  96. Cardiac risk after craniopharyngioma therapy. Pediatr Neurol. 2008 Apr; 38(4):256-60. View Abstract

  97. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. View Abstract

  98. Schwann cell proliferation during Wallerian degeneration is not necessary for regeneration and remyelination of the peripheral nerves: axon-dependent removal of newly generated Schwann cells by apoptosis. Mol Cell Neurosci. 2008 May; 38(1):80-8. View Abstract

  99. Introduction: survivors of childhood cancer: the new face of developmental disabilities. Dev Disabil Res Rev. 2008; 14(3):183-4. View Abstract

  100. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007 Dec 01; 13(23):7022-8. View Abstract

  101. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View Abstract

  102. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer. 2007 Jan; 46(1):53-66. View Abstract

  103. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View Abstract

  104. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer. 2006 Sep 12; 6:223. View Abstract

  105. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View Abstract

  106. Medulloblastoma Subtypes Defined by Gene Expression Analysis 864. Neurosurgery. 2006 Aug 01; 59(2):475. View Abstract

  107. Everyday cognitive function after craniopharyngioma in childhood. Pediatr Neurol. 2006 Jan; 34(1):13-9. View Abstract

  108. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A. 2005 Dec 06; 102(49):17745-50. View Abstract

  109. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15545-50. View Abstract

  110. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care. 2005 Aug; 21(8):527-8. View Abstract

  111. A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res. 2005 Jul 01; 65(13):5683-9. View Abstract

  112. Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics. 2005 Jun; 115(6):e742-8. View Abstract

  113. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005 May; 64(5):391-7. View Abstract

  114. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005 Mar; 72(1):77-84. View Abstract

  115. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):374-9. View Abstract

  116. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View Abstract

  117. Intracerebral abscess in children: historical trends at Children's Hospital Boston. Pediatrics. 2004 Jun; 113(6):1765-70. View Abstract

  118. Neural development and the ontogeny of central nervous system tumors. Neuron Glia Biol. 2004 May; 1(2):127-33. View Abstract

  119. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004 Mar 15; 18(6):629-40. View Abstract

  120. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004 Mar 15; 22(6):994-8. View Abstract

  121. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg. 2003 Dec; 39(6):299-304. View Abstract

  122. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View Abstract

  123. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol. 2003 Nov 01; 263(1):50-66. View Abstract

  124. Progressive myoclonus in a child with a deep cerebellar mass. Neurology. 2003 Sep 23; 61(6):829-31. View Abstract

  125. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol. 2003 Aug; 25(8):644-8. View Abstract

  126. Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery. 2003 Jun; 52(6):1348-56; discussion 1356-7. View Abstract

  127. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol. 2003 May; 62(3):259-67. View Abstract

  128. Application of microarrays to neurological disease. Arch Neurol. 2003 May; 60(5):676-82. View Abstract

  129. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1182-5. View Abstract

  130. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7. View Abstract

  131. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro Oncol. 2002 07; 4(3):165-70. View Abstract

  132. High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors. J Neurobiol. 2002 Jun 15; 51(4):302-12. View Abstract

  133. Focus on central nervous system neoplasia. Cancer Cell. 2002 Mar; 1(2):125-8. View Abstract

  134. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24; 415(6870):436-42. View Abstract

  135. Memory deficits among children with craniopharyngiomas. Neurosurgery. 2001 Nov; 49(5):1053-7; discussion 1057-8. View Abstract

  136. Psychometric testing in bacterial meningitis: results of a long-term prospective study of infants and children treated between 1973 and 1977. J Child Neurol. 2001 Nov; 16(11):854-7. View Abstract

  137. Children with headache suspected of having a brain tumor: a cost-effectiveness analysis of diagnostic strategies. Pediatrics. 2001 Aug; 108(2):255-63. View Abstract

  138. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab. 2001 Jun; 86(6):2890-4. View Abstract

  139. Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int J Cancer. 2000 Jul 20; 89(4):368-77. View Abstract

  140. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90. View Abstract

  141. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol. 2000 May; 48(1):75-81. View Abstract

  142. A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron. 2000 May; 26(2):405-16. View Abstract

  143. Biology and pathobiology of neuronal development. Ment Retard Dev Disabil Res Rev. 2000; 6(1):41-6. View Abstract

  144. Rapid nuclear responses to target-derived neurotrophins require retrograde transport of ligand-receptor complex. J Neurosci. 1999 Sep 15; 19(18):7889-900. View Abstract

  145. Basal ganglia germinoma with progressive cerebral hemiatrophy. Pediatr Neurol. 1999 Apr; 20(4):312-4. View Abstract

  146. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999 Mar; 84(3):895-8. View Abstract

  147. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res. 1999 Feb 01; 59(3):711-9. View Abstract

  148. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci. 1998; 5(1):31-44. View Abstract

  149. Neurotrophins in cerebellar granule cell development and medulloblastoma. J Neurooncol. 1997 Dec; 35(3):347-52. View Abstract

  150. Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci. 1997 Nov 01; 17(21):8293-9. View Abstract

  151. Trk receptors function as rapid retrograde signal carriers in the adult nervous system. J Neurosci. 1997 Sep 15; 17(18):7007-16. View Abstract

  152. Abnormal cerebellar development and foliation in BDNF-/- mice reveals a role for neurotrophins in CNS patterning. Neuron. 1997 Aug; 19(2):269-81. View Abstract

  153. Postnatal addition of satellite cells to parasympathetic neurons. J Comp Neurol. 1996 Nov 18; 375(3):518-25. View Abstract

  154. Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Cancer. 1996 Aug 15; 78(4):864-73. View Abstract

  155. Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci. 1995 Jul; 15(7 Pt 1):4970-81. View Abstract

  156. Neurobehavioral and neurologic outcome in long-term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol. 1995 May; 10(3):209-12. View Abstract

  157. Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood: diagnosis and follow-up. AJNR Am J Neuroradiol. 1995 Apr; 16(4):693-9. View Abstract

  158. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994 Dec 20; 91(26):12867-71. View Abstract

  159. The p53 tumor suppressor gene and pediatric brain tumors. Curr Opin Pediatr. 1994 Dec; 6(6):632-5. View Abstract

  160. Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys. 1994 Oct 15; 30(3):531-9. View Abstract

  161. Advances in radiation therapy for craniopharyngiomas. Pediatr Neurosurg. 1994; 21 Suppl 1:101-7. View Abstract

  162. Vital imaging of glomeruli in the mouse olfactory bulb. J Neurosci. 1992 Mar; 12(3):976-88. View Abstract

  163. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990 Dec 13; 323(24):1651-7. View Abstract

  164. Postnatal construction of neural circuitry in the mouse olfactory bulb. J Neurosci. 1990 Jun; 10(6):1952-66. View Abstract

  165. Neuron/glia relationships observed over intervals of several months in living mice. J Cell Biol. 1988 Sep; 107(3):1167-75. View Abstract

  166. Effect of morphine injectedin periadueductal gray on the activity of single units in nucleus raphe magnus of the rat. Brain Res. 1978 Jun 23; 149(1):266-9. View Abstract

Throughout my career, I have strived to integrate cutting edge science into the practice of medicine and provide holistic care to children with nervous system disorders. My clinical practice and research focus on brain tumors. I served as Chair of the Department of Neurology and Neurologist-in-Chief for more than 19 years ending in October 2024. During my tenure as Chief of Neurology, great emphasis was placed on building world class programs in basic and clinical science, focused clinical practice and translation of scientific discoveries into impactful therapies.

BESbswy